Drug intelligence / Profile preview

timp-1 neutralizing antibody

Development stage
Preclinical
Lead developer
Memorial Sloan Kettering Cancer Center
Modality
Antibody-Based Therapeutics
Administration
Intravenous, Intrathecal
01

Overview

A TIMP-1 neutralizing antibody is a therapeutic agent designed to bind and neutralize Tissue Inhibitor of Metalloproteinases-1 (TIMP-1). TIMP-1 is a multifunctional glycoprotein that canonically acts as an endogenous inhibitor of matrix metalloproteinases (MMPs), but also functions independently as a cytokine-like signaling molecule to promote cell survival, proliferation, and epithelial-mesenchymal transition (EMT). In oncology, TIMP-1 is often upregulated in the tumor microenvironment and is associated with drug resistance, immunosuppression, and metastasis, including leptomeningeal and brain metastasis. Neutralizing antibodies targeting TIMP-1 are being investigated in preclinical models to block its interaction with cell surface receptors (such as CD63) and restore matrix metalloproteinase activity or alleviate local immunosuppression, thereby reducing tumor burden and metastasis.

Other names
anti-TIMP-1 neutralizing antibodyanti-TIMP1 neutralizing antibodyanti-TIMP 1 neutralizing antibodyTIMP-1-neutralizing antibodyTIMP1-neutralizing antibodyTIMP 1-neutralizing antibody
02

Targets

CD63 (Lysosome-associated membrane glycoprotein 3)TIMP1 (Metalloproteinase inhibitor 1)

Beyond the preview

Go deeper on timp-1 neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on timp-1 neutralizing antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call